Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Chrono Therapeutics closes $48m Series B for smart nicotine patch

September 9, 2016 By Sarah Faulkner

Chrono TherapeuticsHayward, Calif.-based startup Chrono Therapeutics reportedly raised $47.6m in a Series B round, led by Kaiser Permanente Ventures.

The money, Chrono CEO Alan Levy told Forbes, is to fund clinical trials of a transdermal smoking cessation patch. The company is preparing for a large, Phase II efficacy study of the technology.

Unlike normal nicotine patches, Chrono said its patches release nicotine during the hours of the day that smokers normally crave a cigarette. The patch is equipped with a Bluetooth-enabled sensor that communicates with the user’s smartphone, so the user can watch in real-time how much nicotine they’ve had in a day.

The company also includes a behavioral component to their device, powered by data provided by the high-tech patch, to ensure that each user is sticking to their cessation plan. If not, the app connects the user with an over-the-phone coach that helps them work through cravings without reaching for a cigarette or another blast of nicotine.

The cessation program runs for 10 weeks, to adhere to FDA standards, during which time the patch slowly lessens the dose of nicotine.

Levy claimed that early clinical data shows their technology does reduce cravings. Nicotine patches by themselves result in 10% cessation success rates, while behavioral changes work in isolation for about 15% of people, according to product management vice president Jenny Hapgood.

By combining pharmaceutical and behavioral approaches, Chrono hope to see quitting rates as high as 60%, Hapgood told Forbes.

“We have made tremendous progress in developing our technology to help people quit smoking, one of the lowest cost ways to improve health and reduce healthcare costs,” chairman & CEO Alan Levy said in prepared remarks. “This financing will bring us closer to commercializing our system for smoking cessation and also enable us to dive more deeply into other applications where we can make a major impact and save lives.”

Filed Under: Drug-Device Combinations, Funding Roundup, mHealth (Mobile Health) Tagged With: Chrono Therapeutics

IN CASE YOU MISSED IT

  • Leo Pharma, Portal Instruments partner to develop needle-free drug delivery device
  • J&J’s Ethicon launches Vistaseal fibrin sealant
  • Senseonics launches Eversense CGM System with non-adjunctive claim
  • ‘Hubble Space Telescope’ for genomics could yield new drugs, materials
  • OncoSec $30m fundraise threatened by spat
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS